打破国外温热治疗仪价格壁垒让普通人都用得起的产品：脊柱养护专家——玉磁温灸

现代研究表明：由于脊柱引发的健康问题要远远高于高血压和心脏病的比例数字，据统计，60％～80％的颈，肩，腰，腿疼痛疾病与脊椎有关：脑、胸、腹、脏器官及其全身系统至少有90多种疾病与脊椎骨、关节应力失衡所产生的些许移位有关，也可以说现代人绝大多数的脊椎存在多多少少。但值得关注的是，由于脊柱养护知识缺乏，使得大多数人都对自己的脊柱疾病一无所知，从而使很多人处于一种亚健康状态而无法解脱。[第一段]     

Leber先天性黑蒙基因研究进展

Leber先天性黑蒙(LCA)是导致婴幼儿先天性盲的严重遗传性视网膜疾病。近年发现，数种与LCA相关的致病基因，主要包括GUCY2D、RPE65、CRX、AIPL1、RPGRIP1和CRB1，其功能涉及视网膜光电信号的传导、维生素A在视网膜的代谢、光感受器细胞的分化和形态发育、蛋白的转运和分布等。针对RPE65的基因治疗在动物实验中取得了一定的成果，将是未来LCA临床治疗的主要研究方向。本就当前LCA的致病基因及其可能的发病机制、基因治疗等方面的研究进展作一综述。     

默克公司2006年第二季度经营状况

默克公司（Merck）2006年第二季度净收益翻番，达到14．99亿美元，而上年同期仅为7．21亿美元。该季度过敏性哮喘治疗药孟鲁司特（montelukast，Singulalr）和疫苗产品的强劲销售部分抵消了降血脂药辛伐他汀（simvastatin，舒降之）专利到期带来的损失，公司销售收入增长6％。同时，默克上调了全年收益预期。     

问题产品

日常食品：四成铝含量超标，劣质牙签：横行大小餐馆，保健品：63种产品违规添加化学药物，减肥食品：检出药物     

放射线联合p53基因及内皮抑素治疗小鼠前列腺癌皮下移植瘤

Objective To test the hypothesis that p53 gene therapy combined with endostatin can enhance tumor response to radiation therapy of RM-1 mouse xenograft prostate cancer and to investigate its mechanism. Methods A mouse prostate cancer model was established. Then mice with xenograft tumor were randomly divided into group A (control), B (radiation), C (radiation and rAdp53), D (radiation and rh-endostatin) and E (radiation and rAdp53 and rh-endostatin). On day 1, rAdp53 was injected intra-tumorously with 1 × 1010 vp per animal to group C and E. From day 1 to 14, rh-endostatin was given 15 mg/kg intraperitoneally daily to group D and E. On day 4 single fraction of 15 Gy was given to tumors in groups B, C, D and E. Normal saline was injected intra-tumorously or intraperitoneaUy accordingly as control. No treatment was done to group A. Tumor volume was measured daily. Samples were collected on Days 5, 10 and 15. Ki67, CD31, p53 and VEGF were detected by means of immunohistochemistry. Results (1) Radiation alone, radiation combined with intra-tumorous injection of Adp53 and/or intraperitoneal injection of rh-endostatin resulted in tumor growth arrest of RM-1 cells in vivo (P = 0.000). Radiation combined with both rAdp53 and rh-endostatin was the most effective treatment (P < 0.05). (2) All the four treatment groups had a decreased expression of mutant type P53 (P = 0.000). The expression of Ki67 in groups B and C were equal (P 0.05) and increasing (P = 0.000), respectively. Group D had a up-down-up curve (P < 0.05), but group E had a up-down one. On day 5 the expresion of VEGF in group E was the lowest (P < 0.05). An increased expression of MVD compared with the control was shown, and MVD in groups C, D and E were always higher than that in the control (P < 0.05). Conclusions The limitation of radiotherapy could be overcome by combination with beth p53 gene therapy and endostatin on the growth of mouse prostate cancer cell. Radiation, rAdp53 and endostatin have their own role but they can be interacted with each other.     

原发性肝癌治疗的新手段——基因治疗

肝细胞癌（HCC）对化疗不敏感，手术切除和肝移植是治疗HCC的有效方法。动脉栓塞术、乙醇注射、射频消融、微波固化、激光热疗、冷冻等局部治疗手段对于无法行手术切除的患者有一定的效果．但复发较常见。且远期存活率无明显提高。近年来，一种新型的治疗手段——基因治疗引起了越来越多学者的关注。现简述HCC发生的分子机制及基因治疗现状。     

贴身潮包星味最浓

如今，从头素到尾的抱款，就算是选用高级皮革制成，也会被打入冷宫。相反，有流苏，雕花和宝石镶嵌的大饱，才是如今最时尚的包款。     

2009年4月份欧洲批准和上市的新产品

获准产品 瑞士医药管理机构Swlssmedic已批准Aurobindo公司的非那雄胺（finasteride）ALP 5mg片剂用于治疗有症状的良性前列腺增生。这是该产品获得的首项批准。     

病理性瘢痕基因治疗的研究进展

病理性瘢痕一直是整形外科治疗中的一个难题，是真皮组织过度增生及细胞基质成分大量沉积的结果，表现为高出皮肤表面并影响外观与功能的异常增生，也称为异常瘢痕。临床上分为增生性瘢痕（hypertrophic scar，HS）及瘢痕疙瘩（keloid,K），目前尚无理想的治疗方法。笔者现从基因治疗的角度出发。探讨病理性瘢痕基因治疗的研究进展及前景。     

欧洲法院的SPC主张将推进生物制药

如果欧洲法院（EcoJ）同意司法部长Philippe Leger于2005年11月24日提出的主张，那么制药厂商在更改产品剂型时，可以获得附加专利保护资格。